AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$GH

Talasaz AmirAli sold $6.3M of GH (indirect holdings)

Talasaz AmirAli (Co-Chief Executive Officer) sold 37,500 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $169.16 ($168.20–$170.29, $6.34M total) across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Talasaz AmirAli
Published Aug 24, 2026, 9:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for Guardant Health.

02

Market read

First public disclosure of a sizable insider sale by Guardant Health's co‑CEO.

03

What to watch

Potential upcoming clinical data releases may offset any negative sentiment from the sale.

Relevance 6/10Novelty 7/10Timing: filed 2026-08-24, reflects same‑day insider activity

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Co-CEO Talasaz AmirAli sold 37,500 shares for $6.34M via open-market transactions on 2026-08-21.

Expected impact

Potential slight dip in GH price over the next few days.

Evidence & confidence

Insider sales by a top executive can be viewed as a negative signal, but the amount ($6.3M) is not material for a mid‑cap biotech.

Market effects

Sector

Minimal impact on broader biotech sector; similar insider sales are common.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Company
    Guardant Health, Inc.

    Biotech firm focused on liquid biopsy diagnostics.

  • Executive
    Talasaz AmirAli

    Co-Chief Executive Officer of Guardant Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GH insider trading history →

Related articles

AUG 25
$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.

pharmaphorum.com2 min
AUG 25
$GHHighAI 8/10

Guardant ordered to pay $245m in DNA sequencing patent dispute

Guardant Health was ordered to pay $245.2m to TwinStrand Biosciences and the University of Washington for patent infringement. The ruling covers 11 products, including Guardant360 CDx, and includes damages, royalties, and interest. Guardant plans to appeal, while TwinStrand affirms its commitment to its intellectual property.

yahoo.com2 min
AUG 17
$GHMed

Guardant Health (GH) Surges on FDA Approval and Cancer Screening Momentum

Aristotle Capital Management’s Core Equity Fund Q2 2026 letter said its fund gained 14.69% in Q2 2026. It highlighted Guardant Health (GH), citing FDA approval of an updated Guardant360 liquid biopsy test, American Cancer Society inclusion of its Shield colorectal screening test, and stronger-than-expected Q1 earnings. GH closed Aug. 14, 2026 near $157.21.

finance.yahoo.com6 min